Recombinant Human High affinity immunoglobulin gamma Fc receptor I (FCGR1A)

What is the basic structure and function of FCGR1A?

FCGR1A is a 72-kDa transmembrane glycoprotein belonging to the Fc-gamma receptor family. It contains an extracellular domain that binds to the Fc portion of IgG with high affinity, a transmembrane region, and a cytoplasmic tail. Functionally, FCGR1A mediates immune responses through antibody-dependent cell-mediated cytotoxicity (ADCC), cell phagocytosis, and clearance of immune complexes. The protein is encoded by a gene located on chromosome 1 and is one of three related gene family members . Unlike other Fc-gamma receptors such as CD32 and CD16, FCGR1A exhibits high-affinity binding to monomeric IgG, making it particularly important in immune surveillance and early response to infection when antibody concentrations are low.

How does FCGR1A differ from other Fc gamma receptors?

FCGR1A (CD64) is distinguished from other Fc gamma receptors (CD32/FcγRII and CD16/FcγRIII) by its high binding affinity for the Fc portion of IgG. While CD32 and CD16 are low to medium-affinity receptors that primarily bind immune complexes or aggregated IgG, FCGR1A can efficiently bind monomeric IgG . This property enables FCGR1A to function effectively in environments with lower antibody concentrations. Additionally, FCGR1A's signaling mechanisms and cellular distribution differ from other Fc receptors, contributing to its unique role in immune function. The receptor's high affinity stems from its three extracellular Ig-like domains compared to the two domains found in other FcγRs.

What are the optimal methods for detecting FCGR1A expression in tissue samples?

For detecting FCGR1A expression in tissue samples, immunohistochemistry (IHC) is widely used and effective. When performing IHC, optimal dilutions of anti-FCGR1A antibodies typically range from 1:100 to 1:500, depending on the specific antibody and tissue type. Antigen retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) is recommended for formalin-fixed paraffin-embedded tissues . Flow cytometry provides quantitative analysis of FCGR1A at the single-cell level, using fluorochrome-conjugated antibodies against CD64. For mRNA expression analysis, quantitative real-time PCR (qRT-PCR) with specific primers targeting the FCGR1A transcript can be employed, as demonstrated in studies examining FCGR1A in ovarian cancer cell lines . RNA-sequencing and single-cell RNA-sequencing offer comprehensive transcriptomic insights into FCGR1A expression patterns across diverse cell populations.

How can recombinant FCGR1A protein be effectively expressed and purified for research use?

Expression of recombinant FCGR1A typically employs mammalian expression systems (HEK293 or CHO cells) to ensure proper glycosylation and folding. The extracellular domain (ECD) of FCGR1A can be fused with a tag (His6, Fc, or GST) to facilitate purification. For optimal expression, codon-optimized cDNA sequences should be used, and the signal peptide should be included to ensure proper secretion. Purification is commonly achieved using affinity chromatography (Ni-NTA for His-tagged proteins or Protein A/G for Fc-fusion proteins), followed by size exclusion chromatography to enhance purity . Critical quality control steps include SDS-PAGE to assess purity, Western blot to confirm identity, ELISA to verify binding activity to IgG, and endotoxin testing to ensure the preparation is suitable for immunological assays.

What experimental approaches are best for studying FCGR1A-mediated signaling pathways?

To study FCGR1A-mediated signaling pathways, several complementary approaches are recommended. Phosphorylation analysis using phospho-specific antibodies against key signaling molecules (Syk, PI3K, Akt) can be performed by Western blot or flow cytometry following FCGR1A crosslinking with immune complexes or anti-FCGR1A antibodies . Proximity ligation assays detect protein-protein interactions within the signaling cascade. For broader pathway analysis, phosphoproteomics using mass spectrometry can identify novel phosphorylation events downstream of FCGR1A activation. Functional readouts including calcium flux assays, cytokine release measurements, and phagocytosis assays provide insights into biological outcomes of FCGR1A signaling. CRISPR/Cas9-mediated gene editing allows precise manipulation of FCGR1A or associated signaling components to establish causality in observed signaling events .

What is the significance of FCGR1A in tumor immune infiltration across different cancer types?

FCGR1A shows significant associations with immune infiltration across multiple cancer types, though with variable patterns. Analysis using the Tumor Immune Estimation Resource (TIMER) has revealed that FCGR1A expression strongly correlates with dendritic cell infiltration in CESC, KIRC, and SKCM (correlation coefficients of 0.682, 0.704, and 0.754, respectively), while in CHOL, it correlates most strongly with neutrophil infiltration (correlation coefficient = 0.778) . FCGR1A expression shows consistent positive correlations with immune marker genes of T cells (CD3E, CD2), monocytes (CD86, CD115), M2 macrophages (CD163, VSIG4, MS4A4A), and dendritic cells (HLA-DPB1, HLA-DRA, HLA-DPA1, ITGAX) across these cancer types, with correlation coefficients frequently exceeding 0.6 . Particularly strong correlations exist between FCGR1A and the T cell exhaustion marker TIM-3 in CESC (r = 0.887) and SKCM (r = 0.934), suggesting potential roles in regulating T cell exhaustion in the tumor microenvironment.

How can FCGR1A be targeted in cancer immunotherapy approaches?

FCGR1A represents a promising target for cancer immunotherapy through several strategies. Bispecific antibodies targeting FCGR1A, such as MDX-447, have shown efficacy in mediating tumor cell lysis in breast cancer models and have progressed to phase II and III clinical trials for prostate and breast cancers . These bispecific antibodies typically engage FCGR1A on immune effector cells while simultaneously binding tumor-associated antigens, redirecting immune cells to attack tumor cells. Alternatively, strategies to modulate FCGR1A expression or function on tumor-associated macrophages could potentially convert immunosuppressive M2-like macrophages toward more anti-tumoral M1-like phenotypes. Engineering therapeutic antibodies with optimized Fc domains to enhance FCGR1A binding can improve antibody-dependent cellular cytotoxicity against tumor cells. Emerging approaches include FCGR1A-targeted nanoparticles for delivering immunomodulatory agents specifically to FCGR1A-expressing cells within the tumor microenvironment.

How should researchers interpret contradictory findings about FCGR1A's prognostic value across different cancer types?

Contradictory findings regarding FCGR1A's prognostic value across cancer types require nuanced interpretation considering multiple factors. The divergent prognostic associations—positive in CESC, CHOL, and SKCM but negative in KIRC—likely reflect distinct tumor microenvironments and immune contexts . When encountering contradictory results, researchers should first consider cancer-specific immune landscapes, as the functional role of FCGR1A-expressing cells may differ based on predominant immune populations present. The developmental origin and tissue-specific biology of different cancers influence how FCGR1A-mediated immune responses impact tumor progression. Additionally, molecular subtypes within each cancer type may show different relationships with FCGR1A expression. Methodological differences across studies, including sample processing, detection methods, cutoff determinations for "high" versus "low" expression, and statistical approaches, can contribute to apparent contradictions. Researchers should evaluate findings in the context of comprehensive immune profiling rather than isolated biomarkers.

What bioinformatic tools and databases are most useful for studying FCGR1A in cancer genomics research?

Several bioinformatic tools and databases are particularly valuable for studying FCGR1A in cancer genomics research. The Gene Expression Profiling Interactive Analysis (GEPIA) platform allows comparison of FCGR1A expression between tumor and normal tissues across multiple cancer types and correlates expression with survival outcomes . Tumor Immune Estimation Resource (TIMER) enables analysis of associations between FCGR1A expression and immune cell infiltration levels or immune marker genes . The STRING database facilitates construction of protein-protein interaction networks involving FCGR1A, helping identify functional partners . For pathway analysis, researchers should utilize Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases to identify biological processes and signaling pathways associated with FCGR1A . The Cancer Genome Atlas (TCGA) provides comprehensive multi-omic data for exploring FCGR1A in various cancer types. Single-cell RNA sequencing databases like the Human Cell Atlas offer insights into cell type-specific expression patterns of FCGR1A within complex tissue environments.

What role does FCGR1A play in immune-related adverse events during cancer immunotherapy?

FCGR1A may contribute to immune-related adverse events (irAEs) during cancer immunotherapy through several mechanisms, though research in this specific area remains limited. As a high-affinity IgG receptor expressed on myeloid cells, FCGR1A can mediate the uptake of antibody-antigen complexes formed between therapeutic antibodies and their targets, potentially triggering inflammatory cascades . In patients receiving monoclonal antibody therapies, FCGR1A-expressing cells may become activated upon binding therapeutic antibodies, contributing to cytokine release and inflammatory reactions. The receptor's role in phagocytosis and antigen presentation may amplify immune responses against not only tumor antigens but also self-antigens, potentially contributing to autoimmune-like toxicities. FCGR1A polymorphisms may influence the risk and severity of irAEs, though this relationship requires further investigation. Monitoring FCGR1A expression on circulating monocytes or tissue-resident macrophages may potentially serve as a biomarker for predicting or monitoring immunotherapy-related adverse events.

How can FCGR1A expression data be integrated into clinical decision-making for personalized cancer treatment?

Integrating FCGR1A expression data into clinical decision-making requires a structured approach. First, standardized immunohistochemistry protocols should be established for reliable FCGR1A detection in clinical samples, with clear scoring systems and cutoff values . For cancers where FCGR1A has demonstrated prognostic significance (CESC, CHOL, KIRC, SKCM), expression data can be incorporated into prognostic models alongside established clinicopathological factors to refine risk stratification . The strong correlation between FCGR1A and immune cell infiltration suggests it could serve as part of an immune signature to predict immunotherapy response . Decision support algorithms can be developed that weigh FCGR1A expression alongside other biomarkers (PD-L1, tumor mutational burden) to guide treatment selection, particularly for immunotherapies. Prospective clinical trials evaluating treatment outcomes stratified by FCGR1A expression levels are needed to validate its predictive utility. Implementation would require integration into electronic health records with clinical decision support tools that provide actionable interpretations of FCGR1A status.

What are the common technical challenges in detecting and quantifying FCGR1A expression, and how can they be overcome?

Researchers frequently encounter several technical challenges when detecting and quantifying FCGR1A expression. Antibody cross-reactivity with other Fc gamma receptors (particularly FCGR1B and FCGR1C) can compromise specificity; this can be addressed by using monoclonal antibodies validated specifically against FCGR1A and confirming specificity using FCGR1A-knockout controls . Variable glycosylation of FCGR1A may affect antibody recognition in certain assays; employing multiple antibodies targeting different epitopes can mitigate this issue. In formalin-fixed paraffin-embedded tissues, antigen masking can occur, necessitating optimization of antigen retrieval protocols (typically using citrate buffer pH 6.0 or EDTA buffer pH 9.0) for each tissue type . For flow cytometry, Fc receptor-mediated non-specific binding of detection antibodies can generate false positives; this can be prevented by pre-blocking samples with purified immunoglobulin or commercial Fc blocking reagents. When analyzing FCGR1A mRNA expression, alternative splicing variants may complicate interpretation; primer design should target conserved regions or specific variants depending on research questions.

How can researchers differentiate between FCGR1A-specific effects and those mediated by other Fc gamma receptors?

Differentiating FCGR1A-specific effects from those mediated by other Fc gamma receptors requires strategic experimental approaches. CRISPR/Cas9 gene editing to create FCGR1A-specific knockouts provides the most definitive method for establishing causality in observed phenotypes . When genetic manipulation is not feasible, FCGR1A-specific blocking antibodies that target unique epitopes not present on other FcγRs can temporarily inhibit FCGR1A function without affecting related receptors. Researchers can exploit FCGR1A's unique high affinity for monomeric IgG by using low concentrations of monomeric IgG that preferentially engage FCGR1A but not lower-affinity FcγRs . Cell models with differential expression of Fc gamma receptors (such as comparing neutrophils with low FCGR1A expression to monocytes with high expression) can help distinguish receptor-specific effects. Careful selection of IgG subclasses with differential binding preferences for various FcγRs can also help isolate FCGR1A-mediated responses. RNA interference approaches targeting specific sequence regions unique to FCGR1A provide another strategy for selective inhibition.

What strategies can address variability in FCGR1A expression across different experimental systems and patient samples?

To address variability in FCGR1A expression across experimental systems and patient samples, several strategies can be implemented. Standardized sample collection, processing, and storage protocols help minimize pre-analytical variables that affect FCGR1A expression . Inclusion of appropriate reference controls in each experimental batch allows normalization and comparison across experiments; for cell lines, well-characterized standards like THP-1 cells (high FCGR1A expressors) can serve as positive controls. When analyzing patient samples, researchers should account for demographic factors, medication use (particularly immunomodulatory drugs), and inflammatory status that may influence FCGR1A expression . For RNA-based detection methods, multiple reference genes should be employed for normalization, selecting those with stable expression across the studied conditions. Flow cytometry experiments should include fluorescence minus one (FMO) controls and report results as molecules of equivalent soluble fluorochrome (MESF) or antibody binding capacity (ABC) units rather than mean fluorescence intensity for better cross-platform comparability. Multi-site validation studies using standardized protocols and reagent lots can establish reproducibility benchmarks for FCGR1A detection methods.